[Anti-vascular endothelial growth factor (VEGF) therapy: a new cause of secondary hypertension].
The formation of new vessels (aka neo-angiogenesis) is critical for tumoral progression. Although anti-angiogenic therapies targeting the vascular endothelial growth factor (VEGF) pathway are employed since less than ten years in human patients, they are now a key player in the treatment of advanced stage malignant tumors. An endothelial syndrome, characterized by hypertension and glomerular proteinuria, complicates this treatment in roughly 25% of patients. From a pathophysiological perspective, this may be considered as a preeclampsia-like syndrome. While the most severe forms require the interruption of the regimen, this syndrome is usually mild or moderate, and should be treated by the addition of an anti-hypertensive drug.
Hertig
Alexandre
A
Urgences néphrologiques et transplantation rénale, Inserm U702, hôpital Tenon, 75020 Paris. alexandre.hertig@tnn.aphp.fr
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000209:etiology*; D009369:Neoplasms / Q000188:drug therapy; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D042442:Vascular Endothelial Growth Factors